The real-world evidence significantly strengthens NRx's NDA filing for NRX-100, especially with regulatory tailwinds from the White House and Congress. Monitor for FDA acceptance of the NDA and any Type C meeting outcomes.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 5 $4.14entry
- T+1 · 5mo ago +4.59%α +4.36% · $4.33
- T+5 · 5mo ago −7.25%α −7.82% · $3.84
- T+20 · 4mo ago −4.71%α −6.57% · $3.95
- T+60 · 3mo ago −15.94%α −19.94% · $3.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.
Key Facts
- IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
- Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
- 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
- NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.
- White House Executive Order and House Appropriations language support use of real-world evidence for depression drug approvals.
- NRx has Fast Track Designation for NRX-100 in suicidal depression and Breakthrough Therapy Designation for NRX-101 in suicidal bipolar depression.
Financial Impact
No financial figures disclosed; potential market opportunity for NRX-100 in suicidal depression (large unmet need) but no revenue or deal value provided.
Risk Factors
- Study limitations: non-randomized design, potential unmeasured confounding variables.
- FDA may still require randomized controlled trials for full approval, despite real-world evidence support.
- NRx is a clinical-stage biopharma with no approved products and no disclosed revenue.
- Competition from existing esketamine (Spravato) and other NMDA-targeting therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307371 |
Track record
22 reports on NRXP
8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers